Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intermediate Endpoint Proposals For Cancer Immunotherapies Don’t Sway FDA

Executive Summary

An issue brief laying out four potential intermediate endpoints for checkpoint modulators draws a cautious response from FDA representatives at a cancer research conference. The endpoints may prove useful for exploratory purposes but are far from ready to serve as the basis for registration, agency says.

You may also be interested in...

Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label

Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.

Weak Result Stops Pfizer’s Tremelimumab Phase III Trial

Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.

Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA

Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts